Reckitt says numerous cases filed generically against baby formula makers-March 2024-www.financetom.com

Reckitt says numerous cases filed generically against baby formula makers

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Reckitt says numerous cases filed generically against baby formula makers

Mar 18, 2024 5:05 AM

LONDON, March 18 (Reuters) - Reckitt said on

Monday that "numerous" cases had been filed generically against

baby formula makers, but that how many directly related to the

Enfamil maker was unclear.

An Illinois jury last week ordered Reckitt unit Mead

Johnson to pay $60 million to the mother of a premature baby who

died of an intestinal disease after being fed the company's

Enfamil baby formula.

Previous page： CenterPoint Energy Finalizes Sale of Louisiana and Mississippi Gas Utilities to Bernhard Capital Partners Next page： Qualcomm considers takeover offer for UK's Alphawave

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

CenterPoint Energy Finalizes Sale of Louisiana and Mississippi Gas Utilities to Bernhard Capital Partners

Apr 1, 2025

09:05 AM EDT, 04/01/2025 (MT Newswires) -- CenterPoint Energy ( CNP ) said Tuesday it completed the sale of its natural gas distribution utilities in Louisiana and Mississippi to affiliates of Bernhard Capital Partners. The utility company previously said in February 2024 it was selling the businesses to the private equity firm for $1.2 billion. The company said the assets...

Qualcomm considers takeover offer for UK's Alphawave

Apr 1, 2025

April 1 (Reuters) - Chipmaker Qualcomm said on Tuesday it is considering making an offer to acquire UK-based Alphawave IP Group ( AWEVF ). ...

Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases

Apr 1, 2025

09:05 AM EDT, 04/01/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, both rare kidney diseases. The company said the application is based on results from a late-stage trial that...

Looming trade tariffs have yet to hit demand for flights, Walsh says

Apr 1, 2025

LONDON (Reuters) - The head of global airlines body IATA said threatened U.S. trade tariffs were unlikely to halt a post-COVID surge in travel demand, and that President Donald Trump's approach could ultimately be positive for the industry. It's additional uncertainty which we never welcome but we've always been able to manage, IATA's Willie Walsh said in an interview, as...